(Q37075927)

18 August 2017

1 reference

title

From bench to bedside: future potential for the translation of prolactin inhibitors as breast cancer therapeutics (English)

1 reference

18 August 2017

1 reference

Charles V Clevenger

1

1 reference

18 August 2017

Jiamao Zheng

2

1 reference

18 August 2017

Elizabeth M Jablonski

3

1 reference

18 August 2017

Traci L Galbaugh

4

1 reference

18 August 2017

Feng Fang

5

1 reference

18 August 2017

language of work or name

1 reference

2 February 2008

1 reference

Journal of Mammary Gland Biology and Neoplasia

18 August 2017

1 reference

18 August 2017

13

1 reference

18 August 2017

1

1 reference

18 August 2017

147-156

1 reference

https://scigraph.springernature.com/pub.10.1007/s10911-008-9074-8

18 August 2017

0 references

cites work

Identification of the immunophilins capable of mediating inhibition of signal transduction by cyclosporin A and FK506: roles of calcineurin binding and cellular location

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10911-008-9074-8

A human prolactin antagonist, hPRL-G129R, inhibits breast cancer cell proliferation through induction of apoptosis.

21 January 2018

1 reference

12 December 2020

Rational design of potent antagonists to the human growth hormone receptor

1 reference

12 December 2020

Autocrine-mediated activation of STAT3 correlates with cell proliferation in breast carcinoma lines

1 reference

12 December 2020

S179D prolactin: antagonistic agony!

1 reference

12 December 2020

The role of prolactin in mammary carcinoma

1 reference

12 December 2020

Prolactin acts as a potent survival factor for human breast cancer cell lines.

1 reference

12 December 2020

Structural and thermodynamic bases for the design of pure prolactin receptor antagonists: X-ray structure of Del1-9-G129R-hPRL

1 reference

12 December 2020

The role of prolactin and growth hormone in breast cancer

1 reference

12 December 2020

Insulin-like growth factor-I, its binding proteins (IGFBP-1 and IGFBP-3), and growth hormone and breast cancer risk in The Nurses Health Study II

1 reference

12 December 2020

Clinical trial of 2-Br-α-ergocryptine (CB154) in advanced breast cancer

1 reference

12 December 2020

Model for growth hormone receptor activation based on subunit rotation within a receptor dimer

1 reference

12 December 2020

Prolactin as a Chemoattractant for Human Breast Carcinoma

1 reference

12 December 2020

Prolactin and murine mammary tumorigenesis: a review

1 reference

12 December 2020

In vivo studies of the anti-tumor effects of a human prolactin antagonist, hPRL-G129R.

1 reference

12 December 2020

Role of prolactin/prolactin receptor signaling in human breast cancer.

1 reference

12 December 2020

In Vitro Model Systems for the Study of Hormone-Dependent Human Breast Cancer

1 reference

12 December 2020

Regulation of bcl-2 gene expression in human breast cancer cells by prolactin and its antagonist, hPRL-G129R

1 reference

12 December 2020

The effects of autocrine human growth hormone (hGH) on human mammary carcinoma cell behavior are mediated via the hGH receptor

1 reference

12 December 2020

Secretion of specific nonphosphorylated and phosphorylated rat prolactin isoforms at different stages of the estrous cycle.

1 reference

12 December 2020

Role of cyclophilin B in prolactin signal transduction and nuclear retrotranslocation

1 reference

12 December 2020

Human growth hormone and extracellular domain of its receptor: crystal structure of the complex

1 reference

12 December 2020

First-line, single-agent Herceptin(R) (trastuzumab) in metastatic breast cancer. a preliminary report

1 reference

12 December 2020

Structure and evolution of the growth hormone gene family

1 reference

12 December 2020

Targeting Stat3 with G-quartet oligodeoxynucleotides in human cancer cells

1 reference

12 December 2020

Development of pure prolactin receptor antagonists.

1 reference

12 December 2020

Tamoxifen plus bromocriptine versus tamoxifen plus placebo in advanced breast cancer: results of a double blind multicentre clinical trial

1 reference

12 December 2020

Activation of the prolactin receptor but not the growth hormone receptor is important for induction of mammary tumors in transgenic mice.

1 reference

12 December 2020

Role of cyclophilins in somatolactogenic action

1 reference

12 December 2020

Novel roles of unphosphorylated STAT3 in oncogenesis and transcriptional regulation

1 reference

12 December 2020

Further investigations on induction of mammary cancer in mice by isografts of hypophyseal tissue.

1 reference

12 December 2020

Loss of mammary epithelial prolactin receptor delays tumor formation by reducing cell proliferation in low-grade preinvasive lesions.

1 reference

12 December 2020

Novel association of Vav2 and Nek3 modulates signaling through the human prolactin receptor

1 reference

12 December 2020

Mammary tumour induction by pituitary isografts in mice.

1 reference

12 December 2020

Growth signaling and JAK2 association mediated by membrane-proximal cytoplasmic regions of prolactin receptors

1 reference

12 December 2020

Incidence of de-novo breast cancer in women chronically immunosuppressed after organ transplantation

1 reference

12 December 2020

Prolactin induces ERalpha-positive and ERalpha-negative mammary cancer in transgenic mice

1 reference

12 December 2020

A novel and functional interaction between cyclophilin A and prolactin receptor

1 reference

12 December 2020

Calcium signalling in T cells stimulated by a cyclophilin B-binding protein

1 reference

12 December 2020

S179D-human PRL, a pseudophosphorylated human PRL analog, is an agonist and not an antagonist

1 reference

12 December 2020

Evidence for a second receptor binding site on human prolactin.

1 reference

12 December 2020

Anti-growth action on mouse mammary and prostate glands of a monoclonal antibody to prolactin receptor

1 reference

12 December 2020

The intranuclear prolactin/cyclophilin B complex as a transcriptional inducer

1 reference

12 December 2020

Ligand-independent dimerization of the human prolactin receptor isoforms: functional implications.

1 reference

12 December 2020

Activation of receptor-associated tyrosine kinase JAK2 by prolactin

1 reference

12 December 2020

Estrogen regulates the serum level of phosphorylated prolactin in mice.

1 reference

12 December 2020

Structural variants of prolactin: occurrence and physiological significance.

1 reference

12 December 2020

Prolactin as a mitogen in mammary cells

1 reference

12 December 2020

Human prolactin and its antagonist, hPRL-G129R, regulate bax and bcl-2 gene expression in human breast cancer cells and transgenic mice.

1 reference

12 December 2020

Effect of bromocriptin treatment on prolactin and steroid receptor levels in human breast cancer

1 reference

12 December 2020

Treatment for chronic myelogenous leukemia: the long road to imatinib

1 reference

12 December 2020

p21-activated protein kinase gamma-PAK in pituitary secretory granules phosphorylates prolactin

1 reference

12 December 2020

Loss of Stat5a delays mammary cancer progression in a mouse model.

1 reference

12 December 2020

Biological activity of phosphorylated and dephosphorylated bovine prolactin

1 reference

12 December 2020

Prolactin potentiates transforming growth factor alpha induction of mammary neoplasia in transgenic mice

1 reference

12 December 2020

The weak immunosuppressant cyclosporine D as well as the immunologically inactive cyclosporine H are potent inhibitors in vivo of phorbol ester TPA-induced biological effects in mouse skin and of Ca2+/calmodulin dependent EF-2 phosphorylation in vit

1 reference

12 December 2020

The X-ray structure of a growth hormone-prolactin receptor complex

1 reference

12 December 2020

Dephosphorylation of standard prolactin produces a more biologically active molecule: evidence for antagonism between nonphosphorylated and phosphorylated prolactin in the stimulation of Nb2 cell proliferation

1 reference

12 December 2020

Effect of endostatin on spontaneous tumorigenesis of mammary adenocarcinoma in a transgenic mouse model

1 reference

12 December 2020

Inhibition of oncogene STAT3 phosphorylation by a prolactin antagonist, hPRL-G129R, in T-47D human breast cancer cells

1 reference

12 December 2020

Development of recombinant human prolactin receptor antagonists by molecular mimicry of the phosphorylated hormone.

1 reference

12 December 2020

Prolactin is a local growth factor in rat mammary tumors

1 reference

12 December 2020

In vitro studies of a prolactin antagonist, hPRL-G129R in human breast cancer cells

1 reference

12 December 2020

Serum immunoreactive and bioactive lactogenic hormones in advanced breast cancer patients treated with bromocriptine and octreotide

1 reference

12 December 2020

The role of human prolactin and its antagonist, G129R, in mammary gland development and DMBA-initiated tumorigenesis in transgenic mice.

1 reference

12 December 2020

Mechanism-based design of prolactin receptor antagonists.

1 reference

12 December 2020

New homologous bioassays for human lactogens show that agonism or antagonism of various analogs is a function of assay sensitivity

1 reference

12 December 2020

Targeting Stat3 in cancer therapy

1 reference

12 December 2020

Development and potential clinical uses of human prolactin receptor antagonists

1 reference

12 December 2020

Prolactin synthesis and secretion by human breast cancer cells

1 reference

12 December 2020

Ternary complex between placental lactogen and the extracellular domain of the prolactin receptor

1 reference

12 December 2020

Biological properties of human prolactin analogs depend not only on global hormone affinity, but also on the relative affinities of both receptor binding sites

1 reference

12 December 2020

Two wrongs can make a right: dimers of prolactin and growth hormone receptor antagonists behave as agonists

1 reference

12 December 2020

The human growth hormone (hGH) antagonist G120RhGH does not antagonize GH in the rat, but has paradoxical agonist activity, probably via the prolactin receptor

1 reference

12 December 2020

Development of new prolactin analogs acting as pure prolactin receptor antagonists

1 reference

12 December 2020

Inhibition of constitutively active Stat3 suppresses growth of human ovarian and breast cancer cells

1 reference

12 December 2020

Inhibition of prolactin (PRL)-induced proliferative signals in breast cancer cells by a molecular mimic of phosphorylated PRL, S179D-PRL.

1 reference

12 December 2020

Prolactin antagonist-endostatin fusion protein as a targeted dual-functional therapeutic agent for breast cancer

1 reference

12 December 2020

Sequence-function relationships within the expanding family of prolactin, growth hormone, placental lactogen, and related proteins in mammals

1 reference

12 December 2020

Nek3 kinase regulates prolactin-mediated cytoskeletal reorganization and motility of breast cancer cells

1 reference

12 December 2020

Phosphorylation of prolactin.

1 reference

12 December 2020

Development of a prolactin receptor-targeting fusion toxin using a prolactin antagonist and a recombinant form of Pseudomonas exotoxin A.

1 reference

12 December 2020

Prophylaxis of spontaneously developing mammary carcinoma in C3H-HeJ female mice by suppression of prolactin.

1 reference

12 December 2020

Human prolactin (hPRL) antagonists inhibit hPRL-activated signaling pathways involved in breast cancer cell proliferation

1 reference

12 December 2020

Transcriptional changes underlying the secretory activation phase of mammary gland development.

1 reference

12 December 2020

A novel design of targeted endocrine and cytokine therapy for breast cancer.

1 reference

12 December 2020

A molecular mimic of phosphorylated prolactin markedly reduced tumor incidence and size when DU145 human prostate cancer cells were grown in nude mice.

1 reference

12 December 2020

S179D prolactin increases vitamin D receptor and p21 through up-regulation of short 1b prolactin receptor in human prostate cancer cells

1 reference

12 December 2020

The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth

1 reference

12 December 2020

10.1007/S10911-008-9074-8

Identifiers

DOI

1 reference

18 August 2017

1 reference